Oncóloga Médica, Departamento Básico de Medicina, Universidad de la República, Montevideo, Uruguay.
Mass General Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Hematol Oncol Clin North Am. 2024 Oct;38(5):973-995. doi: 10.1016/j.hoc.2024.05.006. Epub 2024 Jul 8.
Melanoma, a malignant tumor of melanocytes, poses a significant clinical challenge due to its aggressive nature and high potential for metastasis. The advent of targeted therapy has revolutionized the treatment landscape of melanoma, particularly for tumors harboring specific genetic alterations such as BRAF V600E mutations. Despite the initial success of targeted agents, resistance inevitably arises, underscoring the need for novel therapeutic strategies. This review explores the latest advances in targeted therapy for melanoma, focusing on new molecular targets, combination therapies, and strategies to overcome resistance.
黑色素瘤是一种恶性肿瘤,来源于黑色素细胞,由于其侵袭性和高转移潜能,给临床治疗带来了极大的挑战。靶向治疗的出现彻底改变了黑色素瘤的治疗格局,特别是针对携带特定基因改变(如 BRAF V600E 突变)的肿瘤。尽管靶向药物最初取得了成功,但耐药性不可避免地出现,这凸显了需要新的治疗策略。本文综述了黑色素瘤靶向治疗的最新进展,重点介绍了新的分子靶点、联合治疗以及克服耐药性的策略。